New versions of Bluebird Bio’s gene therapy for inherited blood disorders yielded significant benefits for patients, according to updated results from ongoing clinical trials released Friday.

But whether those benefits will endure for the patients with those conditions, beta-thalassemia and sickle cell disease, remains an open question, even as the Cambridge-based biotech prepares to submit for its first marketing approval in Europe by the end of the year.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • So the Trump FDA is refusing and resisting putting this encouraging new treatment and possible cure to sickle cell disease on fast track review and approval because and why? Obvious answer with Trump & Pence and McConnell and Ryan…..what demographic is impacted by sickle cell disease? African-Americans!

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy